Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Aug-Sep;81(2-3):165-70.
doi: 10.1016/j.plefa.2009.05.020. Epub 2009 Jun 18.

The essentiality of arachidonic acid and docosahexaenoic acid

Hau D Le  1 , Jonathan A Meisel, Vincent E de Meijer, Kathleen M Gura, Mark Puder
Affiliations
Review

The essentiality of arachidonic acid and docosahexaenoic acid

Hau D Le et al. Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep.

Abstract

Objective: The purpose of this review is to correlate the clinical finding that patients receiving parenteral nutrition with a fish oil-based lipid emulsion do not develop essential fatty acid deficiency (EFAD) with an experimental murine model, thus showing that arachidonic acid (AA) and docosahexaenoic acid (DHA) are likely to be the essential fatty acids.

Background: Conventional belief is that linoleic acid (LA, omega-6) and alpha-linolenic acid (ALA, omega-3) are the essential fatty acids (EFAs). We have shown that a fish oil-based lipid emulsion containing AA (omega-6) and docosahexaenoic acid (omega-3) and insignificant quantities of LA and ALA is efficacious in the treatment of parenteral nutrition-associated liver disease (PNALD), a major cause of liver-related morbidity and mortality. The prospect of using a fish oil-based lipid emulsion as monotherapy has raised concerns of EFAD development, hindering its adoption into clinical practice.

Design: Data from patients in our institution who received PN with a fish oil-based lipid emulsion was reviewed for clinical and biochemical evidence of EFAD, defined as an elevated triene-tetraene ratio (Mead acid/AA>0.2). We also investigated the minimum amount of fish oil required to prevent EFAD in a murine model and determined whether DHA and AA alone can prevent EFAD.

Results: No patients receiving PN with a fish oil-based lipid emulsion in our institution have developed biochemical or clinical evidence of EFAD such as an elevated triene-tetraene ratio, growth retardation or dermatitis. This observation parallels our previously published animal studies, which demonstrated prevention of EFAD when 13% of total calories were from fish oil. Moreover, current work in our laboratory shows that AA and DHA provision alone is sufficient to prevent biochemical and physiologic evidence of EFAD in a murine model.

Conclusions: When dosed appropriately, fish oil-based lipid emulsions contain sufficient EFAs to prevent EFAD. Furthermore, AA and DHA alone may be the true EFAs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pathway of metabolism and synthesis of omega-3, omega-6, and omega-9 PUFAs (adapted and modified from Lee et. al.) (52)
Figure 2
Figure 2
Eicosanoids synthesis from arachidonic acid and docosahexaenoic acid (adapted from Lee et al) (52)
See this image and copyright information in PMC

References

    1. Voet DV, JG . Biochemistry. 3rd ed J. Wiley & Sons; New York: 2004.
    1. Das UN. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J. 2006;1:420–39. - PubMed
    1. Burr GO, Burr MM. Nutrition classics from The Journal of Biological Chemistry 82:345-67, 1929. A new deficiency disease produced by the rigid exclusion of fat from the diet. Nutr Rev. 1973;31:248–9. - PubMed
    1. Burr GO, Burr MM. On the nature and role of the fatty acids essential in nutrition. The Journal of Biological Chemistry. 1930;86
    1. Burr GO, Burr MM, Miller ES. On the fatty acids essential in nutrition. III. The Journal of Biological Chemistry. 1932;97:9.

MeSH terms